2022
58 Prevalence of and Risk Factors for Cardiac, Pulmonary, and Neurologic Dysfunction Following Hematopoietic Cell Transplant for Sickle Cell Disease: A STAR Study
Stenger E, Chellapandian D, Shah R, Gillepsie S, Xiang Y, Bhatia M, Chaudhury S, Eckrich M, Guilcher G, Jaroscak J, Kasow K, Krajewski J, Ngwube A, Olson T, Rangarajan H, Horan J, Krishnamurti L, Shenoy S, Abraham A. 58 Prevalence of and Risk Factors for Cardiac, Pulmonary, and Neurologic Dysfunction Following Hematopoietic Cell Transplant for Sickle Cell Disease: A STAR Study. Transplantation And Cellular Therapy 2022, 28: s49-s51. DOI: 10.1016/s2666-6367(22)00219-6.Peer-Reviewed Original Research
2019
How I treat sickle cell disease with hematopoietic cell transplantation
Stenger E, Shenoy S, Krishnamurti L. How I treat sickle cell disease with hematopoietic cell transplantation. Blood 2019, 134: 2249-2260. PMID: 31697818, PMCID: PMC6923666, DOI: 10.1182/blood.2019000821.Peer-Reviewed Original ResearchConceptsHematopoietic cell transplantationSickle cell diseaseCell transplantationCell diseaseOrgan dysfunctionSCD patientsSignificant morbidityEarly mortalityClinical trialsAvailable cureSCD recipientsAlternative donorsIndividual patientsClinical practicePatientsTransplantationClinical vignettesDiseaseOutcomesMorbidityDysfunctionMortalityTrialsRecipients